Role of plasmapheresis in the treatment of paraneoplastic cerebellar degeneration;Značenje plazmafereze u liječenju paraneoplastične cerebelarne degeneracije

Acta Medica Croatica

Volumn 58, Issue 1, 2004, Pages 63-66

  Bašić Jukić, Nikolina ^a   Kes, Petar ^a   Bašić Kes, Vanja ^b   Brunetta, Bruna ^a  

^a KBC Zagreb   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Anti Yo antibodies; Paraneoplastic cerebellar degeneration; Paraneoplastic syndrome; Plasmapheresis

Indexed keywords

ANTIBODY; ANTIGEN; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; GLUCOCORTICOID; IMMUNOGLOBULIN; PROTEIN; AUTOANTIBODY; CDR2 PROTEIN, HUMAN; DNA BINDING PROTEIN; NERVE PROTEIN; TUMOR PROTEIN;

ADULT; CASE REPORT; CEREBELLUM DEGENERATION; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC SYNDROME; PLASMAPHERESIS; REVIEW; ARTICLE; BLOOD; FEMALE; IMMUNOLOGY; MIDDLE AGED; OVARY TUMOR; PARANEOPLASTIC NEUROPATHY;

AUTOANTIBODIES; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; OVARIAN NEOPLASMS; PARANEOPLASTIC CEREBELLAR DEGENERATION; PLASMAPHERESIS;

EID: 1942424900     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and pathophysiology. Brain Pathol 1999; 9: 275-84.
2. Henson RA, Urich H. Cancer and the nervous system. Oxford: Blackwell Scientific, 1982, 314-34.
3. Mayer M, Čikeš N. Paraneoplastički autoimuni neurološki sindromi. Lijec Vjesn 1998; 120: 32-7.
4. Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992; 42: 1938-43.
5. Trotter Lj, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol 1976; 33: 660-1.
6. Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983; 14: 609-13.
7. Greenlee JE, Dalmau J, Lyons T, Clawson S, Smith RH, Pirch HR. Association of anti-Yo antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. Ann Neurol 1999; 45: 805-9.
8. Dropcho EJ, Chen YT, Posner JB, Old Lj. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA 1987; 84: 4552-6.
9. Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 1997; 17: 1406-15.
10. Fumeaux HM, Rosenblum MK, Dalmau J i sur. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322: 1844-51.
11. Mason WP, Graus F, Lang B, Honnorat J i sur. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myastenic syndrome. Brain 1997; 120: 1279-300.
12. Dalmau J, Gultekin SH, Voltz R i sur. Mal, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122: 27-39.
13. Graus F, Dalmau J, Valldeoriola F, Ferrer I, Rene R. Immunological characterization of a neuronal antibody (anti-tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74: 55-61.
14. Sillevis Smitt P, Kinoshita A, De Leeuw B. Paraneoplastic cerebellar ataxia due to autoantobodies against a glutamate receptor. N Engl J Med 2000; 342: 21-9.
15. Gahring LC, Twyman RE, Greenlee JE, Rogers SW. Autoantibodies to neuronal glutamate receptors in patients with paraneoplastic neurodegenerative syndrome enhance receptor activation. Mol Med 1995; 1: 245-53.
16. Antoine JC, Honnorat J, Camdessanche JP i sur. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49: 214-21.
17. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndrome. J Neurol Neurosurg Psychiatry 1996; 61: 270-8.
18. Keime-Guibert F, Graus F, Fleury A i sur. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68: 479-82.
19. Rojas I, Graus F, Keime-Guibert F i sur. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55: 713-5.
20. Graus F, Vega F, Delattre JY i sur. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies. Neurology 1992; 42: 536-40.
21. David YB, Warner E, Levitan, Sutton DM, Malkin MG, Dalmau JO. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. Cancer 1996; 78: 2153-6.
22. Brashear HR, Greenlee JE, Jaeckle KA, Rose JW. Anticerebellar antibodies in neurologically normal patients with ovarian neoplasms. Neurology 1989; 39: 1605-9.